SCHEMBL5582633

SCHEMBL5582633

CCN(CC)CCOC(=O)c1ccc(NC(=O)c2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.69
ALDH1A1 P00352 1/20 0.69
MCHR1 Q99705 7/20 0.65
NPC1 O15118 1/20 0.61
GAA P10253 1/20 0.61
RAB9A P51151 1/20 0.61
PTPN1 P18031 1/20 0.59
TDP1 Q9NUW8 1/20 0.56
CYP2D6 P10635 1/20 0.55
TSHR P16473 1/20 0.55
MAOA P21397 1/20 0.55
HTR3A P46098 1/20 0.55
HRH3 Q9Y5N1 1/20 0.55
THRB P10828 2/20 0.55
MAPT P10636 2/20 0.55
BLM P54132 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
SCN1A P35498 1/20 0.54
SCN2A Q99250 1/20 0.54
SCN3A Q9NY46 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14082932 0.85 MAPT (0.63) SMN1; SMN2ALDH1A1MCHR1NPC1GAA
SCHEMBL9865362 0.83 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1NPC1GAARAB9A
SCHEMBL9645441 0.83 SMN1; SMN2 (0.86) SMN1; SMN2ALDH1A1NPC1GAARAB9A
SCHEMBL14083866 0.82 TRPV1 (0.61) SMN1; SMN2ALDH1A1MCHR1MAPTSCN1A
SCHEMBL5583042 0.81 TDP1 (0.81) SMN1; SMN2ALDH1A1MCHR1TDP1TSHR
SCHEMBL3364980 0.81 HPGD (0.68) SMN1; SMN2ALDH1A1NPC1RAB9ACYP2D6
SCHEMBL14083002 0.81 MCHR1 (0.53) SMN1; SMN2ALDH1A1MCHR1NPC1RAB9A
SCHEMBL3079077 0.81 MAPT (0.62) SMN1; SMN2ALDH1A1NPC1GAARAB9A
SCHEMBL453815 0.80 TSHR (0.71) SMN1; SMN2ALDH1A1TDP1CYP2D6TSHR
SCHEMBL4247732 0.80 SMN1; SMN2 (0.73) SMN1; SMN2ALDH1A1MCHR1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-7115750-B1 Melanin concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed
EP-1218336-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2002-07-03 EP disclosed
WO-2001021577-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173498-A1 Melanin concentrating hormone antagonist MC1R, MCHR1, MCHR2 SMN1; SMN2 3652/4885ALDH1A1 1784/4885MCHR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.